JUNS
NASDAQ · Pharmaceuticals
Jupiter Neurosciences Inc
$0.33
-0.01 (-3.26%)
Financial Highlights (FY 2026)
Revenue
22.5K
Net Income
-9,360,563
Gross Margin
80.6%
Profit Margin
-39,655.5%
Rev Growth
-67.6%
D/E Ratio
0.04
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 80.6% | 80.6% | 63.0% | 63.0% |
| Operating Margin | -40,865.7% | -36,779.4% | 30.2% | 30.1% |
| Profit Margin | -39,655.5% | -37,672.7% | 23.1% | 24.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 22.5K | 69.3K | 3.89M | 4.34M |
| Gross Profit | 18.1K | 55.9K | 2.45M | 2.74M |
| Operating Income | -9,195,188 | -25,502,832 | 1.17M | 1.31M |
| Net Income | -9,360,563 | -25,961,499 | 896.5K | 1.08M |
| Gross Margin | 80.6% | 80.6% | 63.0% | 63.0% |
| Operating Margin | -40,865.7% | -36,779.4% | 30.2% | 30.1% |
| Profit Margin | -39,655.5% | -37,672.7% | 23.1% | 24.9% |
| Rev Growth | -67.6% | -67.6% | +2.3% | +6.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 211.6K | 211.6K | 3.14M | 3.77M |
| Total Equity | 6.03M | 6.03M | 13.36M | 15.30M |
| D/E Ratio | 0.04 | 0.04 | 0.24 | 0.25 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -9,596,827 | -28,095,487 | 1.23M | 1.59M |
| Free Cash Flow | — | — | 754.2K | 863.0K |